Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2010/091/001280
CTRI/2010/091/001280
Completed
Phase 4

A multicentre, open label, observational, non-interventional study to evaluate the safety and effectiveness of liraglutide in subjects with type 2 diabetes mellitus in India

ovo Nordisk India Private Ltd0 sites1,386 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealth Condition 1: null- Diabetes Mellitus, Type 2Health Condition 2: E11- Type 2 diabetes mellitus

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Health Condition 1: null- Diabetes Mellitus, Type 2Health Condition 2: E11- Type 2 diabetes mellitus
Sponsor
ovo Nordisk India Private Ltd
Enrollment
1386
Status
Completed
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
April 30, 2012
Last Updated
4 years ago
Study Type
Pms

Investigators

Sponsor
ovo Nordisk India Private Ltd

Eligibility Criteria

Inclusion Criteria

  • •Subjects with Type 2 Diabetes, including newly\-diagnosed patients / those already receiving other anti\-diabetic medications including GLP\-1 analogues, who require treatment with liraglutide according to the clinical judgment of their treating physician
  • •Subjects who are capable of giving study\-specific signed informed consent before any collection of information
  • •Age 18 years and older

Exclusion Criteria

  • •Subjects with type 1 diabetes
  • •Subjects who are or have previously been on liraglutide
  • •Subjects who have previously been enrolled in the study
  • •Subjects who are participating in another clinical trial
  • •Subjects with a hypersensitivity to liraglutide or to any of the excipients (Disodium phosphate dihydrate, propylene glycol, phenol, water for injections)
  • •Subjects who are pregnant, breast feeding or have the intention of becoming pregnant within the following 6 months

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Observational study comparing the safety and tolerability of Somatuline (Registered trade mark) Autogel (Registered trade mark) injected by Health Care Professionals and patients who inject at home for the treatment of acromegaly.AcromegalyMetabolic and Endocrine - Other metabolic disorders
ACTRN12608000606381Ipsen Pty Ltd38
Completed
Not Applicable
Observational study comparing the safety and tolerability of Somatuline (Registered trade mark) Autogel (Registered trade mark) injected by Health Care Professionals and patients who inject at home for the treatment of neuroendocrine tumours.euroendocrine TumoursNeuroendocrine TumoursCancer - Neuroendocrine tumour (NET)
ACTRN12609000226202Ipsen Pty Ltd25
Active, not recruiting
Phase 1
Abiraterone treatment for patients with relapsed ovarian cancer.
EUCTR2013-000293-29-GBThe Royal Marsden NHS Foundation Trust47
Completed
Not Applicable
A prospective, open label, multi-centre, observational, post-market study evaluating Juvéderm® Volift with Lidocaine for the correction of moderate to severe nasolabial folds (NLF)gezichtverouderingdermal fillersfacial aging
NL-OMON37130Allergan Pharmaceuticals Ireland23
Recruiting
Phase 4
A post marketing surveillance study to evaluate safety and efficacy of fixed dose combination of Ceftriaxone + Sulbactam (Sulbactomax) in patients with various bacterial infectionsHealth Condition 1: null- LRTI, UTI, BACTERIAL MENINGITIS, BACTERIAL SEPSIS, SKIN AND SOFT TISSUE INFECTION, GONORRHOEA, OTITIS MEDIA, SURGICAL PROPHYLAXIS, ENTERIC FEVER (TYPHOID FEVER), BONE AND JOINT INFECTIONS
CTRI/2012/04/002558Venus Remedies Limited2,500